Expression of Tumor Necrosis Factor--related Apoptosis-inducing Ligand Receptors 1 and 2 in Melanoma

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2006 Jun 17

PMID 16778114

Citations 19

Authors

Mary M McCarthy

Kyle A DiVito

Mario Sznol

Daniela Kovacs

Ruth Halaban

Aaron J Berger

Keith T Flaherty

Robert L Camp

Rossitza Lazova

David L Rimm

Harriet M Kluger

Affiliations

Soon will be listed here.

Abstract

Purpose: The proapoptotic receptors tumor necrosis factor--related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and TRAIL-R2 are targets of drugs in clinical development, and receptor expression levels may be important determinants of sensitivity to receptor agonists. We assessed TRAIL-R1 and TRAIL-R2 expression patterns in a large cohort of melanomas and benign nevi.

Experimental Design: We analyzed tissue microarrays containing 546 melanomas and 540 nevi using our automated quantitative method to measure protein levels in situ (AQUA). The system uses S100 to define pixels as melanoma (tumor mask) within the array spot and measures intensity of TRAIL-receptor expression using Cy5-conjugated antibodies within the mask. AQUA scores were correlated with clinical and pathologic variables.

Results: TRAIL-R1 and TRAIL-R2 expression was higher in melanomas than in nevi (P < 0.0001), and higher in primary than in metastatic specimens (P = 0.0031 and P < 0.0001, respectively). TRAIL-R1 and TRAIL-R2 expression exceeding the 95th percentile for nevi was found in 19% and 74% of melanoma specimens, respectively. Although on univariate analysis, high TRAIL-R2 expression correlated with increased survival (P = 0.0439), it was not associated with survival within the primary or metastatic subcohorts. TRAIL-R1 expression was not associated with survival.

Conclusions: TRAIL-R1 and TRAIL-R2 expression is higher in malignant melanocytes than in their benign counterparts, suggesting that these receptors might be effective therapeutic targets in melanoma. Expression is higher in early-stage disease than in metastatic specimens, and expression exceeding that found in nevi is found in a substantially larger fraction of melanomas for TRAIL-R2 compared with TRAIL-R1. Assessment of baseline tumor TRAIL receptor expression may be important in analysis of clinical trials involving TRAIL receptor agonists.

Citing Articles

Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma.

Su D, Schoenfeld D, Ibrahim W, Cabrejo R, Djureinovic D, Baumann R J Immunother Cancer. 2024; 12(3).

PMID: 38519058 PMC: 10961546. DOI: 10.1136/jitc-2023-008646.

The effect of hesperetin on estrogen receptor gene expression and its relationship with the downstream pathways of estrogen receptor alpha.

Bideh M, Safari S, Khedri A, Zangooei M Mol Biol Rep. 2023; 50(9):7225-7236.

PMID: 37418087 DOI: 10.1007/s11033-023-08616-w.

Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.

Jilaveanu L, Puligandla M, Weiss S, Wang X, Zito C, Flaherty K Clin Cancer Res. 2017; 24(1):217-223.

PMID: 29066509 PMC: 5904512. DOI: 10.1158/1078-0432.CCR-17-1555.

Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology.

Naoum G, Buchsbaum D, Tawadros F, Farooqi A, Arafat W Oncol Rev. 2017; 11(1):332.

PMID: 28584572 PMC: 5432952. DOI: 10.4081/oncol.2017.332.

PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.

Kluger H, Zito C, Turcu G, Baine M, Zhang H, Adeniran A Clin Cancer Res. 2017; 23(15):4270-4279.

PMID: 28223273 PMC: 5540774. DOI: 10.1158/1078-0432.CCR-16-3146.

References

Buchsbaum D, Zhou T, Grizzle W, Oliver P, Hammond C, Zhang S . Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res. 2003; 9(10 Pt 1):3731-41. View

Kelley R, Totpal K, Lindstrom S, Mathieu M, Billeci K, DeForge L . Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem. 2004; 280(3):2205-12. DOI: 10.1074/jbc.M410660200. View

DiVito K, Berger A, Camp R, Dolled-Filhart M, Rimm D, Kluger H . Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Res. 2004; 64(23):8773-7. DOI: 10.1158/0008-5472.CAN-04-1387. View

Berger A, Camp R, DiVito K, Kluger H, Halaban R, Rimm D . Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer Res. 2004; 64(23):8767-72. DOI: 10.1158/0008-5472.CAN-04-1384. View

Shankar S, Chen X, Srivastava R . Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate. 2004; 62(2):165-86. DOI: 10.1002/pros.20126. View

Wu J, Zhang X, Gillespie S, Hersey P . Selection for TRAIL resistance results in melanoma cells with high proliferative potential. FEBS Lett. 2005; 579(9):1940-4. DOI: 10.1016/j.febslet.2005.02.041. View

Motoki K, Mori E, Matsumoto A, Thomas M, Tomura T, Humphreys R . Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res. 2005; 11(8):3126-35. DOI: 10.1158/1078-0432.CCR-04-1867. View

Bron L, Scolyer R, Thompson J, Hersey P . Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma. Pathology. 2005; 36(6):561-5. DOI: 10.1080/00313020400011268. View

Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C . HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer. 2005; 92(8):1430-41. PMC: 2361994. DOI: 10.1038/sj.bjc.6602487. View

10.

Garraway L, Widlund H, Rubin M, Getz G, Berger A, Ramaswamy S . Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005; 436(7047):117-22. DOI: 10.1038/nature03664. View

11.

McCarthy M, Sznol M, DiVito K, Camp R, Rimm D, Kluger H . Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res. 2005; 11(14):5188-94. DOI: 10.1158/1078-0432.CCR-05-0158. View

12.

Kurbanov B, Geilen C, Fecker L, Orfanos C, Eberle J . Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Invest Dermatol. 2005; 125(5):1010-9. DOI: 10.1111/j.0022-202X.2005.23900.x. View

13.

Berger A, Davis D, Tellez C, Prieto V, Gershenwald J, Johnson M . Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res. 2005; 65(23):11185-92. DOI: 10.1158/0008-5472.CAN-05-2300. View

14.

Chapman P, Einhorn L, Meyers M, Saxman S, Destro A, Panageas K . Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999; 17(9):2745-51. DOI: 10.1200/JCO.1999.17.9.2745. View

15.

Nguyen T, Thomas W, Zhang X, Gray C, Hersey P . Immunologically-mediated tumour cell apoptosis: the role of TRAIL in T cell and cytokine-mediated responses to melanoma. Forum (Genova). 2000; 10(3):243-52. View

16.

Grossman D, Kim P, Schechner J, Altieri D . Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A. 2001; 98(2):635-40. PMC: 14640. DOI: 10.1073/pnas.98.2.635. View

17.

Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters S, Koeppen H . Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol. 2001; 166(8):4891-8. DOI: 10.4049/jimmunol.166.8.4891. View

18.

Nguyen T, Zhang X, Hersey P . Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin Cancer Res. 2001; 7(3 Suppl):966s-973s. View

19.

Franco A, Zhang X, Van Berkel E, Sanders J, Zhang X, Thomas W . The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol. 2001; 166(9):5337-45. DOI: 10.4049/jimmunol.166.9.5337. View

20.

Mitsiades C, Treon S, Mitsiades N, Shima Y, Richardson P, Schlossman R . TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood. 2001; 98(3):795-804. DOI: 10.1182/blood.v98.3.795. View